4.9.7.4Vertical
Specialty Drug Management
PBMs and specialty pharmacy companies managing high-cost biologics.
Market snapshot
These figures describe Pharmacy Benefits Management (PBM) (4.9.7), the segment that Specialty Drug Management sits within — not Specialty Drug Management on its own.
- Market size
- ~$284B
- Growth
- ~9.9%CAGR (2017–22, nominal)
- Companies
- ~7,700
FragmentationConsolidatedEstimate
U.S. Census Bureau 2022 CBP/Economic Census, NAICS 524292 (Pharmacy Benefit Management & Other TPA); revenue largely reflects drug-cost pass-through, not value-add.
Business model & economics
Revenue model
Management fees, rebates, and spread on drug flows
Key economics
- Recurring revenue
- High
- EBITDA margin
- Thin on gross flows; concentrated in rebate/spread economics
- Capex intensity
- Low
multi-year benefit-management contracts
Characteristics
- Tight oligopoly vertically integrated with insurers.
- At the center of drug-pricing flows.
- Rebate/spread models under intense regulatory scrutiny.
M&A deal context
Deal activityModerate
Who’s acquiring
- Integrated payer-PBMs
- Transparent-PBM challengers
- Health-services strategics
What’s driving deals
- Vertical integration with payers and pharmacy.
- Regulatory and reform scrutiny reshaping the model.
- Transparent-PBM challengers entering the market.
Find Specialty Drug Management acquisition targets
Search Acquisera’s index for companies classified under Specialty Drug Management (4.9.7.4) and build a targeted deal pipeline.
Search companies